Danaher Corporation, the industrial and life sciences conglomerate, has seen its stock trade at a premium to peers for years. But after a rough stretch and a leadership transition, that premium has narrowed. Now, RBC Capital Markets says the valuation is back in line—and it's raising its price target to $250 from $215.
The move comes after Danaher's second-quarter earnings missed expectations, but the bank sees reasons for optimism. Specifically, RBC points to diagnostics—a key segment for the company—turning a corner, and bioprocessing, another major business line, improving.
What's behind the upgrade?
Danaher is a diversified company that makes everything from lab equipment to water quality monitors. Its diagnostics division, which includes testing platforms and consumables, has been under pressure as demand for COVID-related products faded. But RBC believes that pressure is easing, and the segment is poised for a recovery.
Bioprocessing, which supplies tools for drug manufacturers, has also been soft as customers worked through inventory. The bank sees that improving as well, which could provide a tailwind for the company's overall growth.
The leadership transition—Danaher recently named a new CEO—may have added to the uncertainty, but RBC's view is that the company's fundamentals are stabilizing.
What it means for investors
For everyday investors, the key takeaway is that Danaher's stock may no longer be as expensive relative to its peers as it once was. That could make it more attractive to value-oriented investors who had been put off by the premium.
But it's important to remember that a price target is just one analyst's opinion. RBC's $250 target implies upside from current levels, but there's no guarantee the stock will reach it.
Investors should also consider the broader market environment. With US services growth cooling but price pressures keeping a Fed hike in play, interest rates remain a key factor for growth stocks like Danaher. Higher rates tend to weigh on valuations, especially for companies with longer-duration earnings.
Danaher's business at a glance
Danaher operates through three main segments: life sciences, diagnostics, and environmental & applied solutions. The life sciences segment sells instruments and consumables for research and drug development. Diagnostics includes clinical testing and point-of-care products. Environmental & applied solutions covers water quality and industrial products.
The company has a history of acquiring and integrating businesses, which has helped it grow. But it also means its results can be lumpy, as it digests new acquisitions and divests others.
What to watch next
Investors will be watching Danaher's next earnings report to see if the improvements RBC anticipates actually materialize. Key metrics to track include growth in diagnostics and bioprocessing orders, as well as any commentary on the leadership transition.
Also worth noting: Danaher's stock has been a steady performer over the long term, but it's not immune to market swings. Global markets can be volatile, and individual stocks can move for reasons unrelated to fundamentals.
For those considering an investment, it's always wise to do your own research and consider how a stock fits into your overall portfolio. RBC's upgrade is a positive signal, but it's just one piece of the puzzle.
In summary, RBC's price target hike reflects a belief that Danaher's worst days may be behind it. The valuation is more reasonable, and the business appears to be stabilizing. Whether the stock reaches $250 remains to be seen, but the outlook is certainly brighter than it was a few months ago.
